Science signaling:胰腺癌转移新套路——借力神经转移

2015-08-14 佚名 生物谷

近日,来自美国约翰霍普金斯Kimmel癌症中心的科学家在胰腺癌细胞中发现一种新的分子关系能够帮助解释胰腺癌转移的原因。美国每年有大约50,000人罹患胰腺癌,并且诊断后的5年生存率只有5%,而这一研究发现的促癌转移关键分子可能为胰腺癌治疗提供新的靶点。Annexin A2是一种参与多种癌症并导致病人生存率低下的蛋白分子。在这项发表在国际学术期刊science signaling的研究中,研究人员发

近日,来自美国约翰霍普金斯Kimmel癌症中心的科学家在胰腺癌细胞中发现一种新的分子关系能够帮助解释胰腺癌转移的原因。美国每年有大约50,000人罹患胰腺癌,并且诊断后的5年生存率只有5%,而这一研究发现的促癌转移关键分子可能为胰腺癌治疗提供新的靶点。

Annexin A2是一种参与多种癌症并导致病人生存率低下的蛋白分子。在这项发表在国际学术期刊science signaling的研究中,研究人员发现annexin A2能够引导一种叫做Sema3D的蛋白"逃逸"出胰腺癌细胞,一旦离开细胞,Sema3D能够与另外一种分子联结在一起助力癌细胞转移。

之前研究表明在神经细胞生长发育过程中,Sema3D能够引导神经细胞的轴突进行伸展,但人们对于Sema3D与胰腺癌转移之间存在何种关联了解较少。

研究人员利用胰腺癌小鼠模型进行了研究,他们发现在缺少annexin A2的小鼠体内,胰腺癌细胞分泌的Sema3D下降了70倍。而在进行的另外一项实验中,23只缺失annexin A2的胰腺癌模型小鼠均未发生可见的转移瘤,而可产生annexin A2的17只小鼠中有16只在肝脏,肺或腹腔内出现了转移瘤。

研究人员还对胰腺导管腺癌病人的组织进行了分析,同样发现Sema3D在组织内的丰度与转移性胰腺癌进展之间存在显著关联。同时,研究人员还指出,Sema3D似乎还与手术切除胰腺肿瘤的病人出现胰腺癌复发有关。

领导该项研究的Lei Zheng博士及其同事指出,他们还不清楚Sema3D究竟如何促进胰腺癌转移,但根据之前关于Sema3D功能的报道,他们认为Sema3D可能通过帮助癌细胞包绕和追踪神经远离主体瘤实现癌细胞的转移。

原文出处:

K. Foley, A. A. Rucki, Q. et al.Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.Science Signaling.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]
    2015-09-27 楚秀娟
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]
    2015-08-25 superfan

    应该关注一下这方面的进展

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]
    2015-08-16 jichang
  6. [GetPortalCommentsPageByObjectIdResponse(id=2036129, encodeId=c7032036129fe, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sun Sep 27 02:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793961, encodeId=38d21e93961bd, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Nov 19 06:00:00 CST 2015, time=2015-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794077, encodeId=981c1e9407731, content=<a href='/topic/show?id=fef316308dc' target=_blank style='color:#2F92EE;'>#signaling#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16308, encryptionId=fef316308dc, topicName=signaling)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 17 15:00:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36068, encodeId=3e7436068e5, content=应该关注一下这方面的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c041603376, createdName=superfan, createdTime=Tue Aug 25 22:15:00 CST 2015, time=2015-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375081, encodeId=2d4913e508147, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590270, encodeId=9fac15902e0ce, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Aug 16 00:00:00 CST 2015, time=2015-08-16, status=1, ipAttribution=)]

相关资讯

Nature:胰腺癌的早期诊断和根治或将成为可能

胰腺癌是致死率极高的一种癌症。每100位胰腺癌患者中,只有3位可以存活5年以上,而且,近40年来,此癌症的存活率并没有提高。大多数的胰腺癌患者确诊的时间比较晚,80%的患者在术后有复发现象。  Nature:胞外体蛋白或有助诊断早期乳腺癌  目前关于胰腺癌的研究数据表明,早期检测可以挽救更多的生命,病人可根据早期诊断结果获取手术的资格。由于胰腺癌往往在晚期的时候才被诊断出来,目前只有15%左右

新型尿检方法诊断胰腺癌准确率达90%!

随着医学的发展,人们已经意识到了疾病检查方法与治疗手段同样重要。这个道理在肿瘤的治疗和预防中显得尤为重要。据此,长期以来世界各国的科学家们都致力于开发新的肿瘤检测方法。 最近来自英国和西班牙的科学家开发出了一种新型尿检方法有望提高检测胰腺癌的效率,这一结果也已经被发表在Clinical Cancer Research。 胰腺癌是一种恶性肿瘤,当现有检查手段确诊胰腺癌时,这种疾病往往已经发展

Sci Rep:又一重大研究发现——MM41有望成为胰腺癌治疗的新方法

Science Daily:又一重大研究发现——MM41有望成为胰腺癌治疗的新方法近日,来自UCL的研究人员设计出一种新型化合物,可将小鼠胰腺癌肿瘤生长降低80%。该研究成果于2015年6月16日在线发表于 Scientific Reports。该化合物名称为MM41,旨在阻断基因缺陷,可以靶向DNA中的小节(四联体),这种四联体与正常DNA不同,只存在于缺陷基因中。这些发现表明MM41对存在于大

Nat commu:ATM缺失可能是胰腺癌发生和转移的重要因子

                                                        &nbs

Nature:从血液入手早期确诊癌症之王

根据德克萨斯大学MD安德森癌症中心的一项研究,存在于癌症外泌体(exosomes)上的glypican-1 (GPC1)基因编码蛋白,或许可以作为一种潜在非侵入性诊断和筛查工具的组成部分,用来检测有可能尚处于适合手术治疗阶段的早期胰腺癌。这项研究工作发布在6月24日的《自然》(Nature)杂志上。 外泌体是由癌细胞分泌的一种微型病毒样大小的颗粒,其中包含着DNA、RNA和蛋白质。科学家们从

Cancer Res:新型药物联合疗法治疗胰腺癌

尽管可以通过手术进行治疗,但如今胰腺癌依然是引起癌症患者死亡的的主要原因之一,而且并没有特别有效的疗法来治疗这种癌症;然而近日,一项刊登于国际杂志Cancer Research上的研究论文中,来自弗吉尼亚联邦大学等处的研究人员通过进行临床前实验发现,利用一种常见的抗生素和实验性药物相结合或许可以有效治疗胰腺癌。 文章中,研究者发现,当将药物Sabutoclax和抗生素米诺环素相结合后或许就